Immunocore Holdings (IMCR) Payables (2019 - 2026)

Immunocore Holdings has reported Payables for 8 years, with the latest figure at $30.2 million in Q1 2026.

• Quarterly Payables rose 3.61% year-over-year to $30.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.2 million (up 3.61% YoY) and the FY2025 annual result came in at $24.4 million, down 2.93% from the prior year.
• Payables advanced to $30.2 million in Q1 2026 per IMCR's latest filing, from $24.4 million in the prior quarter.
• Over five years, Payables peaked at $108.5 million in Q2 2023 and troughed at $15.5 million in Q1 2024.
• A 5-year average of $38.6 million and a median of $24.4 million in 2025 frame the typical range for Payables.
• The sharpest annual moves came in 2024 and 2025: Payables sank 81.62% in 2024, then surged 87.76% in 2025.
• Over 5 years, Payables stood at $88.1 million in 2022, then tumbled by 79.79% to $17.8 million in 2023, then surged by 41.03% to $25.1 million in 2024, then dropped by 2.93% to $24.4 million in 2025, then rose by 23.78% to $30.2 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $30.2 million, $24.4 million, and $23.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.